Literature DB >> 16030116

Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase.

John K Wiencke1, Kenneth Aldape, Alex McMillan, Joe Wiemels, Michelle Moghadassi, Rei Miike, Karl T Kelsey, Joe Patoka, Jeff Long, Margaret Wrensch.   

Abstract

BACKGROUND: Risk factors for adult glioma in the San Francisco Bay Area include well-known demographic features such as age and race/ethnicity, and our previous studies indicated that these characteristics are associated with the TP53 mutation status of patients' tumors. We enlarged our study to assess the relationships of risk factors with TP53 as well as epidermal growth factor receptor (EGFR) and murine double minute-2 (MDM2) gene amplification and expression and the germ line Leu84Phe polymorphism in the DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT). MGMT expression may depend on the TP53 status of cells.
METHODS: Molecular analyses were carried out on 556 incident astrocytic tumors. MGMT genotype data were collected on germ line DNA from 260 of these cases.
RESULTS: The tumor data confirm the inverse relationships between TP53 mutation and MDM2 (P = 0.04) or EGFR (P = 0.004) amplification and that patients whose tumors contain TP53 mutations are younger than those without (P < 0.001). Although there was little difference in age of patient by EGFR amplification or expression among glioblastoma multiforme cases, EGFR gene amplification was associated with much older age of onset of anaplastic astrocytoma; for example, EGFR-amplified anaplastic astrocytoma cases were on average 63 years old compared with 48 years for nonamplified cases (P = 0.005). An increased prevalence of TP53 mutation positive glioblastoma multiforme was noted among nonwhites (African American and Asian) compared with whites (Latino and non-Latino; P = 0.004). Carriers of the MGMT variant 84Phe allele were significantly less likely to have tumors with TP53 overexpression (odds ratio, 0.30; 95% confidence interval, 0.13-0.71) and somewhat less likely to have tumors with any TP53 mutation (odds ratio, 0.47; 95% confidence interval, 0.13-1.69) after adjusting for age, gender, and ethnicity. Interestingly, EGFR gene amplification and EGFR protein overexpression were also inversely associated with the MGMT 84Phe allele.
CONCLUSIONS: Our results are consistent with ethnic variation in glioma pathogenesis. The data on MGMT show that an inherited factor involving the repair of methylation and other alkylation damage, specifically to the O6 position of guanine, may be associated with the development of tumors that proceed in their development without TP53 mutations or accumulation of TP53 protein and possibly also those that do not involve amplification of the EGFR locus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16030116     DOI: 10.1158/1055-9965.EPI-05-0089

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  28 in total

1.  Tethering function of the caspase cleavage fragment of Golgi protein p115 promotes apoptosis via a p53-dependent pathway.

Authors:  Poh Choo How; Dennis Shields
Journal:  J Biol Chem       Date:  2010-12-08       Impact factor: 5.157

2.  Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics.

Authors:  Quinn T Ostrom; Kathleen M Egan; L Burt Nabors; Travis Gerke; Reid C Thompson; Jeffrey J Olson; Renato LaRocca; Sajeel Chowdhary; Jeanette E Eckel-Passow; Georgina Armstrong; John K Wiencke; Jonine L Bernstein; Elizabeth B Claus; Dora Il'yasova; Christoffer Johansen; Daniel H Lachance; Rose K Lai; Ryan T Merrell; Sara H Olson; Siegal Sadetzki; Joellen M Schildkraut; Sanjay Shete; Richard S Houlston; Robert B Jenkins; Margaret R Wrensch; Beatrice Melin; Christopher I Amos; Jason T Huse; Jill S Barnholtz-Sloan; Melissa L Bondy
Journal:  Int J Cancer       Date:  2019-04-22       Impact factor: 7.396

3.  The survival of patients with high grade glioma from different ethnic groups in South East England.

Authors:  T Ratneswaren; R M Jack; D Tataru; E A Davies
Journal:  J Neurooncol       Date:  2014-08-26       Impact factor: 4.130

4.  Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.

Authors:  Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan
Journal:  J Neurooncol       Date:  2007-05-26       Impact factor: 4.130

Review 5.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

6.  Common genetic variants related to genomic integrity and risk of papillary thyroid cancer.

Authors:  Gila Neta; Alina V Brenner; Erich M Sturgis; Ruth M Pfeiffer; Amy A Hutchinson; Briseis Aschebrook-Kilfoy; Meredith Yeager; Li Xu; William Wheeler; Michael Abend; Elaine Ron; Margaret A Tucker; Stephen J Chanock; Alice J Sigurdson
Journal:  Carcinogenesis       Date:  2011-06-03       Impact factor: 4.944

7.  Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.

Authors:  Wenting Wu; Kathleen R Lamborn; Jan C Buckner; Paul J Novotny; Susan M Chang; Judith R O'Fallon; Kurt A Jaeckle; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12-21       Impact factor: 12.300

8.  Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase.

Authors:  Qingming Fang; Natalia A Loktionova; Robert C Moschel; Sahar Javanmard; Gary T Pauly; Anthony E Pegg
Journal:  Biochem Pharmacol       Date:  2007-10-02       Impact factor: 5.858

9.  The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.

Authors:  Maya Remington; Jana Chtchetinin; Karen Ancheta; Phioanh Leia Nghiemphu; Timothy Cloughesy; Albert Lai
Journal:  Neuro Oncol       Date:  2008-09-23       Impact factor: 12.300

10.  Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.

Authors:  Hailiang Zhang; Baijun Dong; Jiade J Lu; Xudong Yao; Shilin Zhang; Bo Dai; Yijun Shen; Yao Zhu; Dingwei Ye; Yiran Huang
Journal:  BMC Cancer       Date:  2009-07-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.